natgillin/translations-raw huggingface dataset:
Greater improvements at week 12 from baseline compared to placebo were demonstrated in skinspecific health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS-I and HS-II), patient global satisfaction with medication treatment as measured by the Treatment Satisfaction Questionnaire-medication (TSQM; Studies HS-I and HS-II), and physical health as measured by the physical component summary score of the SF-36 (study HS-I). 
Večje izboljšanje v 12. tednu so pokazali glede na izhodiščno vrednost v primerjavi s placebom glede z zdravjem povezane kakovosti življenja, specifične za kožo, merjene z dermatološkim indeksom kakovosti življenja (“Dermatology life quality index” (DLQI), v študijah HS-I in HS-II), glede bolnikovega splošnega zadovoljstva z zdravljenjem z zdravilom, merjenem z vprašalnikom o zadovoljstvu z zdravljenjem z zdravilom (“Treatment Satisfaction Questionnaire - medication” (TSQM), v študijah HS-I in HS-II), in glede telesnega zdravja, merjenega s seštevkom telesnih komponent v vprašalniku SF-36 (“Short Form Health Survey" (SF 36) v študiji HS-I).
The volume for injection is selected based on the patients' height and weight (table 1). 
Volumen za injiciranje se določi glede na bolnikovo višino in telesno maso (glejte preglednico 1).
Treatment with SOLYMBIC may result in the formation of autoimmune antibodies. 
Zdravljenje z zdravilom SOLYMBIC lahko povzroči nastanek avtoimunskih protiteles.
In psoriasis studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75 response from baseline at week 16 (see tables 11 and 12). 
V študijah pri psoriazi I in II je bil primarna končna točka delež bolnikov, ki so od izhodišča do 16. tedna dosegli PASI 75 (glejte preglednici 11 in 12).
During treatment with SOLYMBIC, other concomitant therapies (e.g. corticosteroids and/or immunomodulatory agents) should be optimised. 
Med zdravljenjem z zdravilom SOLYMBIC je treba optimizirati druge sočasne terapije (npr. kortikosteroide in/ali imunomodulacijska zdravila).
Nail psoriasis assessments included the Modified Nail Psoriasis Severity Index (mNAPSI), the Physician's Global Assessment of Fingernail Psoriasis (PGA-F) and the Nail Psoriasis Severity Index (NAPSI) (see table 13). 
Ocena psoriaze nohtov je vključevala prilagojeni indeks izrazitosti psoriaze nohtov (mNAPSI - Modified Nail Psoriasis Severity Index), zdravnikovo globalno oceno psoriaze nohtov (PGA-F - Physician's Global Assessment of Fingernail Psoriasis) in indeks izrazitosti psoriaze nohtov (NAPSI - Nail Psoriasis Severity Index) (glejte preglednico 13).
SOLYMBIC works by reducing this inflammation. 
Zdravilo SOLYMBIC deluje tako, da zmanjša tako vnetje.
1 p value for standard dose versus low dose comparison Immunosuppressant therapy could only be discontinued at or after week 26 at the investigator's discretion if the subject met the clinical response criterion defined as a closure of all fistulas that were draining at baseline for at least 2 consecutive post-baseline visits 
1p vrednost za primerjavo standardnega odmerka proti majhnemu odmerku 2Zdravljenje z imunosupresivi je bilo lahko prekinjeno v 26. tednu ali po njem po raziskovalčevi diskreciji, če je bolnik izpolnjeval kriterije kliničnega odziva 3definiran kot zaprtje vseh fistul, ki so bile prisotne ob začetku študije na vsaj 2 zaporednih obiskih po začetku
Patients who develop a new infection while undergoing treatment with SOLYMBIC, should be monitored closely and undergo a complete diagnostic evaluation. 
Bolnike, pri katerih se med zdravljenjem z zdravilom SOLYMBIC pojavi nova okužba, je treba natančno nadzirati in opraviti morajo popolno diagnostično obravnavo.
SOLYMBIC is also used to treat severe plaque psoriasis in children and adolescents weighing either 23 to 28 kg or 47 kg or greater for whom topical therapy and phototherapies have either not worked very well or are not suitable. 
Zdravilo SOLYMBIC se uporablja tudi za zdravljenje hude luskavice v plakih pri otrocih in mladostnikih, ki tehtajo ali od 23 do 28 kg ali 47 kg ali več, pri katerih lokalno zdravljenje in zdravljenja s svetlobo nista dovolj dobro delovala ali pa nista primerna.
SOLYMBIC can also be used to treat severe, active and progressive rheumatoid arthritis without previous methotrexate treatment. 
Zdravilo SOLYMBIC je mogoče uporabljati tudi za zdravljenje hudega, aktivnega in napredujočega revmatoidnega artritisa brez predhodnega zdravljenja z metotreksatom.
In rheumatoid arthritis, methotrexate is continued while using SOLYMBIC. 
Pri revmatoidnem artritisu se uporaba metotreksata med uporabo zdravila SOLYMBIC nadaljuje.
For subcutaneous use. 
Subkutana uporaba.
After proper training in injection technique, patients may self-inject with SOLYMBIC if their physician determines that it is appropriate and with medical follow-up as necessary. 
Bolniki, ki se naučijo pravilnega postopka injiciranja, si zdravilo SOLYMBIC lahko injicirajo sami, če zdravnik presodi, da je to primerno, in je zagotovljeno ustrezno medicinsko spremljanje.
Two weeks later (day 29) continue with a dose of 40 mg every week. 
Čez dva tedna (29. dan) nadaljujte z odmerkom 40 mg vsak teden.
Among patients who were at least partial responders at week 12, and who received continuous weekly adalimumab therapy, the HiSCR rate at week 48 was 68.3% and at week 96 was 65.1%. 
Med bolniki, ki z vsaj delnim odzivom v 12. tednu, in ki so prejemali neprekinjeno tedensko terapijo z adalimumabom vsak teden, je bila stopnja kliničnega odziva (HiSCR) v 48. tednu 68,3 % in v 96. tednu 65,1 %.
Some of those patients were also treated with azathioprine or 6-mercaptopurine. 
Nekateri od teh bolnikov so bili zdravljeni tudi z azatioprinom ali 6-merkaptopurinom.
Week 12 results showed statistically significant improvement of the signs and symptoms of active non-radiographic axial spondyloarthritis in patients treated with adalimumab compared to placebo (table 9). 
Rezultati po 12. tednu so pokazali statistično pomembno izboljšanje znakov in simptomov aktivnega ne-radiografskega aksialnega spondiloartritisa pri bolnikih, ki so bili zdravljeni z adalimumabom v primerjavi s placebom (preglednica 9).
Bath Ankylosing Spondylitis Disease Activity Index c Ankylosing Spondylitis Disease Activity Score d mean change from baseline e n = 91 placebo and n = 87 adalimumab f high sensitivity C-Reactive Protein (mg/L) g n = 73 placebo and n = 70 adalimumab h 
d povprečna sprememba od začetka zdravljenja e n=91 placebo in n=87 adalimumab f hs-CRP = C-reaktivni protein z veliko občutljivostjo (high sensitivity C-Reactive Protein) (mg/l) g n=73 placebo in n=70 adalimumab h
• A warning message for HCPs treating the patient at any time, including in conditions of emergency, that the patient is using Solymbic. 
• Opozorilo za zdravstvene delavce, ki kadar koli zdravijo bolnika, vključno v izrednih razmerah,
Spondyloarthritis Research Consortium of Canada i n = 84 placebo and adalimumab j n = 82 placebo and n = 85 adalimumab ***, **, * Statistically significant at p < 0.001, < 0.01, and < 0.05, respectively, for all comparisons between adalimumab and placebo 
i n=84 placebo in adalimumab j n=82 placebo in n=85 adalimumab ***, **, * Statistično pomembno pri p < 0,001, < 0,01 in < 0,05, v tem zaporedju, za vse primerjave med adalimumabom in placebom.
The safety and efficacy of adalimumab in children aged 12-17 years have not yet been established for hidradenitis suppurativa. 
Varnost in učinkovitost adalimumaba pri otrocih, starih 12-17 let, za hidradenitis suppurativa ni bila potrjena.
All p-values are pairwise comparisons of proportions for adalimumab versus placebo * p < 0.001 
Vse vrednosti p so za parne primerjave deležev med adalimumabom in placebom * p < 0,001
SOLYMBIC reduces the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and improves physical function. 
Rentgensko slikanje je pokazalo, da zdravilo SOLYMBIC upočasni hitrost napredovanja prizadetosti perifernih sklepov pri bolnikih s poliartikularnimi, simetričnimi podtipi bolezni (glejte poglavje 5.1) in izboljša telesno funkcijo.
PGA: Clear/minimal b a Percent of patients achieving PASI75 response was calculated as centre-adjusted rate b p < 0.001, adalimumab versus placebo 
PGA: čisto/minimalno b a Odstotek bolnikov, ki so dosegli odziv PASI 75, je bil izračunan kot delež, korigiran za center b p < 0,001, adalimumab v primerjavi s placebom
Patients were then retreated with adalimumab 0.8 mg/kg every other week for an additional 16 weeks and response rates observed during retreatment were similar to the previous double-blind period: PASI 75 response of 78.9% (15 of 19 subjects) and PGA clear or minimal of 52.6% (10 of 19 subjects). 
Bolniki so bili nato znova zdravljeni z adalimumabom v odmerku 0,8 mg/kg vsak drugi teden še nadaljnjih 16 tednov, pri čemer so bile opažene stopnje odziva podobne kot v prejšnjem dvojno slepem obdobju: odziv PASI 75 pri 78,9 % (15 od 19 oseb) in PGA čisto ali minimalno pri 52,6 % (10 od 19 oseb).
Administration of live vaccines to infants exposed to adalimumab in utero is not recommended for 5 months following the mother's last adalimumab injection during pregnancy. 
Uporaba živih cepiv pri dojenčkih, ki so bili izpostavljeni adalimumabu in utero, ni priporočljiva 5 mesecev po zadnji injekciji adalimumaba, ki jo je mati prejela med nosečnostjo.
What SOLYMBIC contains - The active substance is adalimumab. 
Kaj vsebuje zdravilo SOLYMBIC - Zdravilna učinkovina je adalimumab.
Table 18 Maintenance of clinical remission and response (percent of patients) 
Preglednica 18: Vzdrževanje klinične remisije in odziva (odstotek bolnikov)
Paediatric Crohn's disease patients < 40 kg: 
Crohnova bolezen pri pediatričnih bolnikih < 40 kg:
a a a p < 0.001, Adalimumab versus placebo 
a a p < 0,001, adalimumab v primerjavi s placebom
At week 4, subjects were randomised 1:1 based on their body weight at the time to either the low dose or standard dose maintenance regimens as shown in table 19. 
V 4.tednu so bili bolniki glede na njihovo telesno maso v tem času randomizirani v razmerju 1:1 bodisi v vzdrževalni režim z majhnim odmerkom ali vzdrževalni režim s standardnim odmerkom, kot kaže preglednica 19.
ASASa 40 
a40
In RA study V, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (see table 7). 
V študiji revmatoidnega artritisa V so strukturno okvaro sklepov ocenili rentgenografsko in jo izrazili kot razliko v modificirani celotni Sharpovi oceni (glejte preglednico 7).
Total Sharp Score c 
Celotna Sharpova ocena c
Paediatric Crohn's disease patients ≥ 40 kg: 
Crohnova bolezen pri pediatričnih bolnikih ≥ 40 kg:
The results for the 40 mg every other week dose are summarised in table 4. 
Rezultati odmerka 40 mg vsak drugi teden so strnjeni v preglednici 4.
Administration of SOLYMBIC is not recommended during pregnancy. 
Uporaba zdravila SOLYMBIC med nosečnostjo ni priporočljiva.
SOLYMBIC can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents (sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), steroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs). 
Zdravilo SOLYMBIC se lahko uporablja skupaj z metotreksatom ali nekaterimi imunomodulirajočimi antirevmatičnimi zdravili (sulfasalazinom, hidroksiklorokinom, leflunomidom in pripravki zlata za injiciranje), steroidi in zdravili proti bolečinam, vključno z nesteroidnimi protivnetnimi zdravili (NSAID).
SOLYMBIC is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. 
Zdravilo SOLYMBIC je indicirano za zdravljenje hude psoriaze v plakih pri otrocih in mladostnikih od 4. leta starosti, ki so se neustrezno odzvali na ali niso ustrezni kandidati za topikalno zdravljenje in fototerapije.
SOLYMBIC slows down the damage to the cartilage and bone of the joints caused by the disease and to improve physical function. 
Zdravilo SOLYMBIC upočasni okvaro sklepnega hrustanca in kosti, ki jo povzroča ta bolezen in izboljšuje telesno delovanje.
If you have mild heart failure and you are being treated with SOLYMBIC, your heart failure status must be closely monitored by your doctor. 
• Če imate blago srčno popuščanje in se zdravite z zdravilom SOLYMBIC, mora zdravnik natančno nadzorovati stanje vašega srčnega popuščanja.
In patients with at least a partial response to adalimumab 40 mg weekly at week 12, the HiSCR rate at week 36 was higher in patients who continued weekly adalimumab than in patients in whom dosing frequency was reduced to every other week, or in whom treatment was withdrawn (see table 16). 
Pri bolnikih z vsaj delnim odzivom na adalimumab v odmerku 40 mg vsak teden v 12. tednu, je bila stopnja kliničnega odziva (HiSCR) v 36. tednu višja pri bolnikih, ki so nadaljevali zdravljenje z adalimumabom vsak teden kot pri bolnikih, pri katerih so pogostnost odmerjanja zmanjšali na vsak drugi teden, ali pri katerih je bilo zdravljenje ukinjeno (glej preglednico 16).
Impaired renal and/or hepatic function 
Okvarjena funkcija ledvic in/ali jeter
Physicians should exercise caution when considering the use of SOLYMBIC in patients with a history of recurring infection or with underlying conditions which may predispose patients to infections, including the use of concomitant immunosuppressive medications. 
Pri odločanju za uporabo zdravila SOLYMBIC je potrebna previdnost pri bolnikih z anamnezo ponavljajoče se okužbe ali z osnovnimi boleznimi, ki lahko zvečajo nagnjenost k okužbam, vključno s sočasno uporabljenimi imunosupresivnimi zdravili.
Systemic lupus erythematosus Lupus-like syndrome 
občasni rabdomioliza, sistemski eritematozni lupus sindrom podoben lupusu
How to use SOLYMBIC 
Kako uporabljati zdravilo SOLYMBIC
The combination of SOLYMBIC and abatacept is not recommended (see section 4.4 “Concurrent administration of biologic DMARDS or TNF-antagonists”). 
Kombinacija zdravila SOLYMBIC in abatacepta ni priporočljiva (glejte poglavje 4.4 “Sočasna uporaba bioloških DMARDS ali antagonistov TNF”).
SOLYMBIC is injected under the skin (subcutaneous use). 
Zdravilo SOLYMBIC se injicira pod kožo (subkutana uporaba).
The recommended dose of SOLYMBIC for patients with enthesitis-related arthritis, aged 6 to 17 years depends on the height and weight of the child. 
Priporočeni odmerek zdravila SOLYMBIC za bolnike z artritisom, povezanim z entezitisom, stare od 6 do 17 let, je odvisen od višine in telesne mase otroka.
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC BIOLOŠKE UČINKOVINE INIZDELOVALCI, ODGOVORNI ZA SPROŠČANJE SERIJ
SOLYMBIC dose in milligrams (mg) by height and weight of patients for enthesitis-related arthritis 
Odmerek zdravila SOLYMBIC v miligramih (mg) glede na višino in telesno maso bolnikov za artritis, povezan z entezitisom
Clinical response is decrease from baseline in Mayo score ≥ 3 points and ≥ 30% plus a decrease in the rectal bleeding subscore [RBS] ≥ 1 or an absolute RBS of 0 or 1; * p < 0.05 for adalimumab versus placebo pairwise comparison of proportions ** p < 0.001 for adalimumab versus placebo pairwise comparison of proportions a 
Klinični odgovor pomeni znižanje ocene Mayo od začetka za ≥ 3 in ≥ 30% ter znižanje podocene rektalne krvavitve [RBS] ≥ 1 ali absolutna RBS 0 ali 1; *p < 0,05 za parno primerjavo deležev med adalimumabom in placebom **p < 0,001 za parno primerjavo deležev med adalimumabom in placebom a Od tistih, ki so izhodiščno prejemali kortikosteroide
Total body weight (kg) 
Celotna telesna masa (kg)
MRI Sacroiliac Joints d,i 
MRI sakroiliakalnih sklepov d,i
On rare occasions, a specific and severe type of lymphoma has been observed in some patients taking adalimumab. 
V redkih primerih so pri nekaterih bolnikih, ki dobivajo adalimumab, opazili specifično in resno obliko limfoma.
Prescribers should exercise caution in considering the use of SOLYMBIC in patients with pre-existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of SOLYMBIC should be considered if any of these disorders develop. 
Pri odločanju za uporabo zdravila SOLYMBIC pri bolnikih z že prej obstoječimi ali nedavno nastalimi demielinizirajočimi boleznimi osrednjega ali perifernega živčevja je potrebna previdnost; če se razvije katera od teh bolezni, je treba razmisliti o prenehanju zdravljenja z zdravilom SOLYMBIC.
Table 22 Response, remission and mucosal healing in study UC-II (percent of patients) 
Odziv, remisija in celjenje sluznice v študiji UC-II (odstotek bolnikov)
What SOLYMBIC looks like and contents of the pack 
Izgled zdravila SOLYMBIC in vsebina pakiranja
Very common Injection site reaction (including injection site erythema) Common 
reakcija na mestu injiciranja (vključno z eritemom na mestu injiciranje)
Vaccinations: if possible children should be up to date with all vaccinations before using SOLYMBIC. 
• Cepljenja: če je mogoče, naj vaš otrok pred začetkom uporabe zdravila SOLYMBIC opravi vsa potrebna cepljenja.
A patient who requires surgery while on SOLYMBIC should be closely monitored for infections, and appropriate actions should be taken. 
Bolnika, ki med zdravljenjem z zdravilom SOLYMBIC potrebuje operacijo, je treba natančno nadzirati glede okužb in ustrezno ukrepati.
Neurologic evaluation should be performed in patients with non-infectious intermediate uveitis prior to the initiation of SOLYMBIC therapy and regularly during treatment to assess for pre-existing or developing central demyelinating disorders. 
Pri bolnikih z neinfekcijskim intermediarnim uveitisom je treba pred začetkom zdravljenja z zdravilom SOLYMBIC in redno med zdravljenjem opravljati nevrološko oceno, da se oceni že obstoječe ali razvijajoče se demielinizirajoče bolezni osrednjega živčevja.
Administration of live vaccines to infants exposed to SOLYMBIC in utero is not recommended for 5 months following the mother's last SOLYMBIC injection during pregnancy. 
Uporaba živih cepiv pri dojenčkih, ki so bili izpostavljeni zdravilu SOLYMBIC in utero, ni priporočljiva še 5 mesecev po materini zadnji injekciji zdravila SOLYMBIC med nosečnostjo.
Packs size of one pre-filled syringe. 
Velikost pakiranja z eno napolnjeno injekcijsko brizgo.
Administration of SOLYMBIC should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled. 
Če se bolniku pojavi nova resna okužba ali sepsa, je treba uporabo zdravila SOLYMBIC prekiniti in uvesti ustrezno protimikrobno ali protimikotično zdravljenje, dokler okužba ni obvladana.
Methotrexate should be continued during treatment with SOLYMBIC. 
Med zdravljenjem z zdravilom SOLYMBIC je treba še naprej uporabljati metotreksat.
SOLYMBIC is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. 
Zdravilo SOLYMBIC je indicirano za zdravljenje zmerne do hude kronične psoriaze v plakih pri odraslih bolnikih, ki so kandidati za sistemsko zdravljenje.
The decision to stop using SOLYMBIC should be discussed with your doctor. 
Če ste prenehali uporabljati zdravilo SOLYMBIC O odločitvi, da bi prenehali uporabljati zdravilo SOLYMBIC, se morate posvetovati s svojim zdravnikom.
SOLYMBIC is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. 
Zdravilo SOLYMBIC je indicirano za zdravljenje odraslih s hudim aksialnim spondiloartritisom brez radiografskega dokaza za AS, toda z objektivnimi znaki vnetja s povišanimi CRP in/ali MRI, ki so nezadostno reagirali na ali ne prenašajo nesteroidnih protivnetnih zdravil.
Children with enthesitis-related arthritis 
Otroci z artritisom, povezanim z entezitisom
On a clean, well-lit work surface, place a new, pre-filled syringe. 
Na čisto, dobro osvetljeno delovno površino položite novo napolnjeno injekcijsko brizgo.
A 40 mg pen, and a 20 mg and 40 mg pre-filled syringes are available for patients to administer a full 20 mg or 40 mg dose. 
40 mg peresnik ter 20 mg in 40 mg napolnjeni injekcijski brizgi so na voljo za bolnike za dajanje polnega 20 mg ali 40 mg odmerka.
Assessments in Ankylosing Spondylitis b Bath Ankylosing Spondylitis Disease Activity Index 
Bathov indeks bolezenske aktivnosti ankilozirajočega spondilitisa (Bath Ankylosing Spondylitis Disease Activity Index)
A. Remove the number of SOLYMBIC pre-filled syringes you need from the package. 
A. Vzemite potrebno število napolnjenih injekcijskih brizg zdravila SOLYMBIC iz škatle.
SOLYMBIC is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). 
Zdravilo SOLYMBIC je indicirano za zdravljenje aktivnega artritisa, povezanega z entezitisom pri bolnikih, starih 6 let in več, ki so se neustrezno odzvali ali so intolerantni za kovencionalno zdravljenje (glejte poglavje 5.1).
Packs sizes of one, two, four and six pre-filled syringes. 
Velikosti pakiranj po ena, dve, štiri in šest napolnjenih injekcijskih brizg.
If you forget to use SOLYMBIC 
Če ste pozabilli uporabiti zdravilo SOLYMBIC
SOLYMBIC is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. 
Zdravilo SOLYMBIC je indicirano za zdravljenje neinfekcijskega intermediarnega, posteriornega uveitisa in panuveitisa pri odraslih bolnikih, ki se niso zadostno odzvali na zdravljenje s kortikosteroidi, pri bolnikih s potrebo po zmanjšani uporabi kortikosteroidov ali pri bolnikih, pri katerih je zdravljenje s kortikosteroidi neprimerno.
Coagulation and bleeding disorders (including activated partial thromboplastin time prolonged), Autoantibody test positive (including double stranded DNA antibody), 
koagulacija in motnje krvavenja (vključno s podaljšanim aktiviranim parcialnim tromboplastinskim časom), prisotnost avtoprotiteles (vključno s protitelesi proti dvovijačni DNA), zvišanje laktat dehidrogenaze v krvi
(up to a maximum of 40 mg) subcutaneously every other week to patients with enthesitis-related arthritis who were 6 to 17 years, the mean trough steady-state (values measured at week 24) serum adalimumab concentrations were 8.8 ± 6.6 µg/mL for adalimumab without concomitant methotrexate and 11.8 ± 4.3 µg/mL with concomitant methotrexate. 
(do največ 40 mg) subkutano vsak drugi teden bolnikom z artritisom, povezanim z entezitisom, ki so bili stari od 6 do 17 let, je bila povprečna najmanjša koncentracija adalimumaba v serumu v stanju dinamičnega ravnovesja (vrednost merjena v 24. tednu) 8,8 ± 6,6 μg/ml med uporabo adalimumaba brez metotreksata in 11,8 ± 4,3 μg/ml med sočasno uporabo metotreksata.
No dose adjustment is required. 
Starejši bolniki Prilagoditev odmerka ni potrebna.
At week 52, 42.9% of patients who received adalimumab/methotrexate combination therapy achieved clinical remission (DAS28 < 2.6) compared to 20.6% of patients receiving methotrexate monotherapy and 23.4% of patients receiving adalimumab monotherapy. 
Po 52. tednih je klinično remisijo (DAS28 < 2,6) doseglo 42,9 % bolnikov, ki so dobivali kombinirano terapijo z adalimumabom/metotreksatom, 20,6 % bolnikov, ki so dobivali metotreksat v monoterapiji, in 23,4 % bolnikov, ki so dobivali adalimumab v monoterapiji.
Table 20 Paediatric CD study PCDAI clinical remission and response 
Študija Crohnove bolezni pri pediatričnih bolnikih PCDAI klinična remisija in odziv
Adalimumab 160/80 mg N = 76 
adalimuma b 160/80 mg N = 76
Table 10 ACR response in placebo-controlled psoriatic arthritis studies (percent of patients) 
Odziv ACR v študijah pri psoriatičnem artritisu, kontroliranih s placebo (odstotek bolnikov)